Background
==========

Unilateral chromosomal losses detected by a loss of heterozygosity (LOH) analysis are the most common genetic events in solid tumors \[[@B1]\]. The level of chromosomal losses, rather than a single loss, has been consistently shown to be a significant predictor of survival in stage II and III gastrointestinal cancer patients \[[@B2]-[@B6]\]. Although chromosomal losses are a part of gene inactivation, in a naïve sense, the LOH events represent a reduction in the dose of genetic elements. A dosage compensation mechanism, which maintains the dose of the human genome, equalizes the difference in the dose of the X chromosome between males (XY) and females (XX) via pan-chromosomal epigenetic inactivation \[[@B7]-[@B9]\]. Therefore, it is important to determine if the level of LOHs underlying the clinical course of gastric cancer is associated with the epigenetic changes occurring in tumor cells as a result of an unbalanced reduction of the genomic dose.

The distributions of the two major repetitive sequences in the human genome, the *Alu*and L1 retroelements, are differentially biased toward the CpG-rich euchromatic and CpG-poor heterochromatic regions, respectively \[[@B10]\]. These self-replicating sequences are suppressed by hypermethylation because the vegetative copy generates integrative copies resulting in the harmful influence of insertion mutagenesis. In addition, the retroelements are known to be potential centres for the spread of CpG methylation to the adjacent CpG sites \[[@B11]-[@B14]\]. The L1 elements can boost the long-distance spread of heterochromatin that is responsible for chromosome X inactivation \[[@B7],[@B15]\]. Meanwhile, high-density *Alu*elements near the CpG-rich islands are believed to spread CpG methylation over short distances \[[@B16]\]. The short-distance spread of *Alu*methylation and the long-distance spread of L1 methylation appear to construct the two distinct chromatin structures.

Repetitive sequences in eukaryotes can initiate and facilitate the spread of RNA-mediated chromatin condensation through the pairing of homologous sequences \[[@B17]\]. Given the interdependence of CpG methylation and chromatin condensation, human retroelements can also cause the spread of RNA-mediated methylation \[[@B15],[@B18]\]. An analysis of the relationship between the length of the CpG islands and the position of the nearest retroelement revealed that the spread of retroelement methylation can influence the size of a CpG island \[[@B16]\]. Unilateral chromosomal losses frequently occurring in tumor cells are accompanied by an irreversible unbalanced decrease in the dose of genomic and transcriptional retroelements. The colorectal cancer genome suffering LOH events undergoes global hypomethylation that affects the L1 retroelements \[[@B19]\]. In addition, a study of gastric cancers reported a close relationship between the high-level LOHs and the hypomethylation changes in the methylated CpGs near the CpG islands \[[@B20]\]. Therefore, the LOH events might reduce the spread of retroelement methylation as well as the methylation of the retroelement copies.

In this study of gastric cancers, the relationship between the LOH events and the spread of retroelement methylation was examined by determining the correlation between the extent of LOHs and the transitional CpG methylation between the CpG islands and retroelements in the 5\'-end regions. The extent of the transitional area was found to be shorter with the nearest *Alu*elements than with the nearest L1 and LTR elements. The 5\'-transitional methylated CpG sites bordered by a low density of *Alu*elements or L1 and LTR elements were frequently hypomethylated in the high-level LOH cases. This suggests that unilateral chromosomal losses reduces the spread of L1 methylation.

Methods
=======

Computational analyses of the human genome
------------------------------------------

Information on the coding and non-coding sequences as well as CpG islands was obtained from the human genome database in the May, 2004 version \[[@B21]\]. A 1-kb sized non-overlapping window was used to analyze the sequence characteristics of a 10-kb segment upstream and downstream from each transcription start site. This window analysis allowed an examination of the major regulatory regions, which are usually rich in protein binding motifs, and at the same time, produced a profile of the 5\'-transitional CpGs between the CpG islands and their nearest retroelements. The sequence data delimited from the promoter regions were input into a local program to calculate the coverage of CpG islands. A CpG island was defined as a DNA segment with a G+C content ≥ 50%, longer than 200 bp nucleotides, and an Observation/Expectation CpG ratio \> 0.6 \[[@B22]\]. A similar procedure was used for the genomic position and annotation of retroelements using the RepeatMasker program \[[@B23]\].

Patients and tumor tissues
--------------------------

The gastric cancer tissue and non-cancerous mucosa were obtained from 50 patients who had undergone surgery between March and December 2003 at St. Paul\'s Hospital, The Catholic University of Korea. These fresh archives provided the genomic DNA that had been amplified efficiently by methylation-specific PCR (MSP). The histological classification of the gastric cancers was carried out according to the Lauren\'s classification \[[@B24],[@B25]\], and the degree of differentiation was graded according to the recommendations of the World Health Organization for the histological typing of gastric cancer \[[@B26]\]. The Tumor-Node-Metastasis (TNM) criteria were used to determine the tumor stage based on the pathological and clinical findings observed from radiography, ultrasonography, computed tomography, and abdominal exploration during laparotomy. The Institutional Review Board approved this study, and written informed consent was obtained from each patient prior to the surgical resection.

A single 5--7 mm diameter tumor site containing a homogeneous cell content was selected from each representative tissue section. Seven-μm-thick hematoxylin-eosin-stained sections were microdissected under a 40-x stereomicroscope using a surgical scalpel. All the microdissected tumor sites were checked for a tumor cell content ≥ 70% prior to DNA extraction. A major fraction (33 sites, 66%) of the microdissected tissues contained a tumor cell content of 80--89%, followed by ≥ 90% (12 sites, 24%) and 70--79% (5 sites, 10%). Approximately 50 microdissected cells were digested in 1 μl of a Tween 20 -- Proteinase K lysis buffer. An average of 100 μl of each microdissected tissue lysate was used for microsatellite analysis, and an average of 500 μl of the same lysate was subjected to bisulfite modification for methylation analysis.

PCR-based microsatellite analysis
---------------------------------

The MSI (microsatellite instability) and LOH status of each gastric cancer was determined using a panel of 40 microsatellite markers on eight cancer-associated chromosomes, 3p, 4p, 5q, 8p, 9p, 13q, 17p, and 18q, as reported elsewhere (figure [1A](#F1){ref-type="fig"}) \[[@B5],[@B6],[@B27]\]. The MSI status of the microsatellite sequences was scored if there were any frameshift mutations in \> 40% of the homozygous markers. The unilateral reduction of the heterozygous allelic bands was interpreted as LOH. The level of LOHs representing a significant reduction in the genomic dose was determined based on the number of chromosomes showing more than one LOH. According to the genetic classification criterion of gastric cancers \[[@B6],[@B27]\], the level of LOHs was divided into low (LOH-L, less than four) and high (LOH-H, four or more losses) levels for the intestinal-type cancers, and baseline (LOH-B, zero or one loss), low (LOH-L, two or three losses), and high (LOH-H, four or more losses) levels for the diffuse-type cancers.

DNA modification by sodium bisulfite
------------------------------------

Because the quality of the formalin-fixed tissue DNA varied, the amount of template DNA was determined based on a PCR band intensity of 20 ng/μl that had been amplified by the microsatellite primer set, *D19S226*(forward, 5\'-CCA GCA GAT TTT GGT GTT GTC TA-3\'; reverse, 5\'-ACA GAG CCA GAG CCA GTA GGA GT-3\'; amplicon size, 164 bp). Ninety microliters of the genomic DNA was denatured with 10 μl of 3 M NaOH for 15 min at 37°C before sodium bisulfite modification. This procedure involved modifying 100 μl of the denatured DNA with 1,040 μl of 2.3 M sodium bisulfite and 60 μl of 10 mM hydroquinone for 12 hr at 50°C, as described elsewhere \[[@B20]\]. The modified DNA was then purified using a genomic DNA purification kit (Promega, Madison, WI, USA), precipitated with ethanol, and dissolved in 35 μl of 5 mM Tris buffer (pH 8.0). One μl aliquot of the modified DNA solution was placed in the PCR tube and stored at -20°C.

Semiquantitative methylation analysis
-------------------------------------

The semiquantitative methylation analysis using a radioisotope was performed in a minimum of amplification rounds for sub-plateau DNA amplification, as described elsewhere \[[@B20]\]. A 1 μl aliquot of the bisulfite-modified DNA was amplified and labeled in 10 μl of a hot-start PCR solution containing an α-^32^P dTTP (PerkinElmer, Boston, MA, USA) and dNTP mixture through 32 PCR cycles. Thirty-two MSP primer sets were selected at the 5\'-end regions of 20 genes using the MethPrimer software \[[@B28]\] (table [1](#T1){ref-type="table"}). The sequences, PCR condition, and genomic position of these primer set are listed in table [2](#T2){ref-type="table"} and \[see [Additional file 1](#S1){ref-type="supplementary-material"}\]. The coverage of CpG islands, the distribution of retrolements, and the MSP primer position are shown in the figure [2](#F2){ref-type="fig"}. Each MSP primer set was designed to generate a small fragment of ≤ 150 bp, and yield a specific PCR intensity using the genomic DNA obtained from the formalin-fixed paraffin-embedded tissues.

The specificity of each MSP primer set was validated using a standard curve for the universal methylated and unmethylated DNA (figure [1B](#F1){ref-type="fig"}). Based on the standard curve of the control MSP bands, the density of the methylated CpGs was classified into 5 levels; level 1 (0--20% methylation), level 2 (21--40% methylation), level 3 (41--60% methylation), level 4 (61--80% methylation), and level 5 (81--100% methylation). The intensity of the MSP bands (figure [3A](#F3){ref-type="fig"}) was compared with the methylated CpG content that was estimated by sequencing the common PCR DNA (figure [3B](#F3){ref-type="fig"}). The methylation levels estimated by the MSP intensities were consistent with the methylation densities measured from the common PCR DNAs in 23 normal (96%) and 20 tumor (83%) DNAs of 24 normal and tumor DNA pairs (table [3](#T3){ref-type="table"}).

In previous studies \[[@B29],[@B30]\], the MSP bands visualized by the ethidium bromide staining were classified into three methylation levels (no, weak, and strong methylation). Forty eight DNA specimens were amplified through 37 PCR cycles, of which six (13%) failed to generate any visible PCR bands by ethidium bromide staining (table [3](#T3){ref-type="table"}). Eight of the 42 visible MSP bands (19%) were scored differently from the common PCR DNA. Twelve of the 14 DNA specimens (85%) showing no visible PCR bands or inaccurate methylation levels were similarly scored by both 32-cycle amplification using a radioisotope and common PCR DNA. This high accuracy of the 32-cycle amplification protocol allowed the MSP bands to be classified into five methylation levels.

When 80 normal and tumor DNA pairs showing a one-level methylation difference were analyzed, 71 pairs (89%) demonstrated same-level methylation differences in the MSP band intensities and the common PCR DNA \[see [Additional file 2](#S2){ref-type="supplementary-material"}\].

Statistical analysis
--------------------

The Pearson\'s correlation coefficient was used to determine the correlation between (i) the MSP band intensity and the proportion of methylated and unmethylated control DNA, (ii) the coverage of CpG islands and the density of retroelements, and (iii) the frequency of methylation alterations and the level of LOHs using SPSS ver. 11.0 software. A *χ*^*2*^test or Fisher\'s exact test and an independent *t*test were used to compare the clinicopathological variables or the frequency of methylation alterations between the different microsatellite genotypes. Two-sided p values \< 0.05 were considered significant.

Results
=======

Analysis of the transitional area between the CpG Islands and the nearest retroelements
---------------------------------------------------------------------------------------

Of a total of 22,297 genes examined, 10,515 and 11,782 were found to have a single CpG island and no CpG islands at the transcription start site, respectively. The densities of *Alu*s, L1s, and LTRs in a 1-kb window were plotted separately a distance 10 kb upstream and downstream from the transcription start sites. Figure [4A](#F4){ref-type="fig"} revealed the following: (i) the densities of the three retroelement types were commonly higher in the extragenic 10-kb regions than in the 10-kb intragenic regions. (ii) the three retroelement types were commonly depressed in both the intragenic and extragenic first 1-kb regions, (iii) the density of depressed retroelements was lower in the first 1-kb regions containing CpG islands than in the regions containing no CpG islands, (iv) the density of *Alu*copies rapidly reached a plateau at a distance of 3 kb, which was higher in the 5\'-end regions containing CpG islands than in the regions containing no CpG islands.

A transitional area between the CpG islands and their nearest retroelements was demarcated by a distance from the 5\'(3\')-end of the CpG island to the position of the nearest retroelement in the extragenic (intragenic) region (figure [4B](#F4){ref-type="fig"}). Figure [4C](#F4){ref-type="fig"} shows that the CpG islands frequently neighbored the nearest *Alu*elements (76% and 83%) and infrequently the nearest L1 (13% and 11%) and LTR (11% and 6%) elements in both the extragenic and intragenic regions. Figure [4D](#F4){ref-type="fig"} shows that the mean extent of the transitional area between the CpG island and the nearest retroelement was significantly shorter in the extragenic regions (989 bp) than in the intragenic regions (1,700 bp). The mean extent of the extragenic and intragenic transitional area bordered by the nearest *Alu*elements (945 bp and 1,645 bp) was significantly shorter than that by the nearest L1 (1,063 bp and 1,853 bp) and LTR (1,104 bp and 1,967 bp) elements.

Genetic classification of gastric cancers according to the level of LOHs
------------------------------------------------------------------------

The allelic profiles of the 40 microsatellite sequences were initially analyzed for a MSI at the homozygous markers that showed a few shadow or stutter bands in a pair of normal and tumor DNAs. Five of 50 gastric cancers examined had a high-frequency MSI in more than 40% of the homozygous alleles examined. A LOH was analyzed at the stable heterozygous alleles in the remaining 45 MSI-negative gastric cancers. The number of chromosomes showing more than one LOH event was counted in each MSI-negative case. Using the number of chromosomal losses, the extents of LOH was categorized into high level involving four or more chromosomes (LOH-H) and low level involving less than four chromosomes (LOH-L) for intestinal-type cancers. One and zero chromosomal loss were scored as baseline-level loss (LOH-B) for diffuse-type cancers. Overall, 20 LOH-H (40%), 19 LOH-L (38%), 6 LOH-B (12%), and 5 MSI (10%) cases were identified in the 50 surgical specimens (table [4](#T4){ref-type="table"}). A comparison of the clinicopathological variables in the LOH-H and LOH-L gastric cancers revealed a lymphatic invasion (p = 0.001) and advanced stage (p = 0.015) to be significantly associated with the LOH-H cases. Intestinal-type cancers (p = 0.032) as well as well and moderate differentiation (p = 0.046) were more frequent in the LOH-L cases.

Relationships between the LOHs and methylation alterations
----------------------------------------------------------

Fifty pairs of normal and tumor tissues were examined using the MSP primer sets for a total of 32 CpG amplicon sites (figure [5](#F5){ref-type="fig"}). The CpG islands of the *CDH1*, *RABGEF1*, and *STAG1*genes, which neighbored a high density of *Alu*elements at a distance \< 2 kb, were found to be hypomethylated in the normal tissues at a level \< 2. These CpG islands showed few methylation alterations in the tumor tissues. The transitional CpGs of the *MYBPC2*gene bordered by the high-density *Alus*were hypermethylated at a level ≥ 3 in the normal tissues but were unchanged in the tumor tissues. The long CpG islands of the *PAX5*and *RUNX2*genes neighboring a small number of retroelements at a long distance, \> 6 kb, showed insignificant methylation alterations in the tumor tissues.

The CpG island boundaries neighboring a low density of *Alu*elements or L1 and LTR elements at a distance of 2--6 kb became increasingly methylated at a level of ≥ 2. The CpG sites in close proximity to the transcription start sites with no accompanying CpG islands were densely methylated at a level of ≥ 3. The CpG island boundaries and the proximal sites of the non-CpG-island genes were categorized as transitional CpGs, because these CpG sites could be distinguished from the proximal sites of the CpG islands that are consistently unmethylated. The methylation level of these 5\'-transitional CpGs in the normal and tumor DNA was compared (table [5](#T5){ref-type="table"}). The methylation level of the LOH-H cancers was significantly lower at the 5\'-transitional CpG sites of the *VDR*, *FLJ43855*, *CDKN2A*, *MUC8*, *MAGEA2*, and *MSLN*genes. The LOH-L cancers had a significantly higher methylation level at the 5\'-transitional CpG sites of the *MLH1*and *CDKN2A*genes.

The frequency of methylation alterations occurring in a total of 14 transitional CpG amplicons was scored according to the number of the amplicons showing a difference in the level of methylation between the normal and tumor DNA. The frequency of hypomethylation and hypermethylation in the transitional CpGs were linearly (r = 0.738, p \< 0.0001) and inversely (r = 0.673, p \< 0.0001) proportional to the number of chromosomal losses, respectively, (figure [6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}). There were significant differences in the mean frequency of hypomethylation (44% versus 15%) and hypermethylation (5% versus 26%) between the LOH-H and LOH-L cancers (p \< 0.0001) (figure [6C](#F6){ref-type="fig"} and [6D](#F6){ref-type="fig"}). The frequency of hypermethylation in the transitional CpGs was highest in the MSI cases.

Although the proximal portion of the CpG islands was largely unmethylated in both the normal and tumor DNAs, the CpG islands of the *MLH1*and *RUNX3*genes was hypermethylated in most tumor tissues with a MSI (*MLH1*) and LOH-B (*RUNX3*), respectively (figure [5](#F5){ref-type="fig"}). The distal portion of the *RUNX3*CpG island was frequently hypermethylated in both LOH-H and LOH-L cases.

Relationships between methylation alterations and the clinicopathological features
----------------------------------------------------------------------------------

The relationship between the frequency of methylation alterations and the clinicopathological features was analyzed in 39 gastric cancers with high-level and low-level chromosomal losses (table [6](#T6){ref-type="table"}). The frequency of hypomethylation in the transitional area increased with increasing lymphatic invasion (p = 0.006) and advanced tumor stage (p = 0.015). The frequency of hypermethylation decreased with increasing venous invasion (p = 0.041), lymphatic invasion (p = 0.003), and advanced tumor stage (p = 0.023).

Of a total of 598 methylation alterations, 472 (79%) showed a one-level difference in methylation between the paired normal and tumor DNA and 126 (21%) showed a two- or higher-level difference with an inverse methylation status between the normal and tumor DNA \[see [Additional file 2](#S2){ref-type="supplementary-material"}\]. The normal tissues of the LOH-H and LOH-L cases showed a similar level of methylation in the transitional area.

Discussion
==========

It was previously reported that the short-distance spread of *Alu*methylation acts as a barrier blocking the long-distance spread of L1 methylation \[[@B16]\]. In this study, the transitional area bordered by *Alu*elements was significantly shorter than that bordered by the L1 elements, which concurs with a previous report \[[@B16]\]. CpG islands neighboring the high-density *Alu*elements were invariably hypomethylated in both the normal and tumor tissues. The long CpG islands of the *PAX5*and *RUNX2*genes that neighbored a few retroelements showed insignificant methylation alterations. The 5\'-transitional methylated CpGs bordered by either low-density *Alu*elements or other retroelements were frequently hypomethylated in the LOH-H cases (table [5](#T5){ref-type="table"}). This suggests that LOH events have no influence on the unmethylated CpG islands that are protected by high-density *Alu*elements. In contrast, the transitional methylated CpG sites under long-distance L1 methylation which are either not protected or only partially protected by the *Alu*elements, were hypomethylated in association with the LOHs.

In a *Drosophila*model, repetitive RNA is believed to diffuse through the nucleus and assemble onto other homologous copies to initiate the spread of the heterochromatin signal \[[@B31]\]. This study found that the intragenic regions contained low-density retroelements compared with the extragenic regions, whereas the transitional area was longer in the intragenic regions than in the extragenic regions (figure [4D](#F4){ref-type="fig"}). The intragenic retroelements releasing RNA, expressed in initial embryogenesis, are believed to have a higher probability for encountering homologous RNA sequences to promote the further spread of methylation compared with extragenic copies releasing fewer RNA. Therefore, the 5\'-transitional CpG sites affected by the RNA-mediated spread of L1 methylation are likely to be hypomethylated as a result of chromosomal losses.

The hypomethylation of imprinted genes is often observed in gastric cancers but not associated with a LOH involving the counterpart chromosome \[[@B32],[@B33]\]. The losses of chromosome 9p (*CDKN2A*) and 3p (*MLH1*) examined in a previous study \[[@B20]\] were not associated with the hypomethylation of the transitional CpGs of the *CDKN2A*and *MLH1*genes. This suggests that epigenetic alterations in response to the LOH events are more likely to result from genome-wide compensation than chromosome by chromosome compensation. Meanwhile, a previous study on colonic cancers reported that the LOH events examined on three chromosomes were associated with global L1 hypomethylation \[[@B19]\]. In this study on gastric cancers, there is a significant difference in L1-associated methylation between the LOH-H and LOH-L cases. Therefore, the reduced spread of methylation in the transitional area is likely due to LOH events accompanying an unbalanced decrease in the genomic L1 dose.

Previous multifocal LOH studies \[[@B6],[@B27],[@B34],[@B35]\] reported that heterogeneous tumor sites shared a similar level of LOHs involving the same and different chromosomes. Interestingly, heterogeneous tumor sites of multidirectionally differentiated cancers such as a glandular-neuroendocrine carcinoma \[[@B34]\], sarcomatoid carcinoma \[[@B35]\], and gastric cancers \[[@B6],[@B20],[@B27]\] frequently demonstrated reciprocal losses involving the opposite alleles on the same chromosome. This suggests that a similar level of LOHs rather than the genomic position drives the subclonal expansion of heterogeneous tumor cells with a similar growth advantage, and that the level of LOHs acts as a stem-line genotype driving tumor progression.

A previous report on multifocal methylation analysis \[[@B20]\] showed that the methylation alterations associated with the level of LOHs were scored differentially in heterogeneous sites from a given gastric cancer. This suggests that chromosomal losses cause sideline methylation alterations and initiate intratumoral methylation heterogeneity. The transitional CpG sites of individual genes mostly demonstrated a one-level difference in the methylation status between normal and tumor tissues \[see [Additional file 2](#S2){ref-type="supplementary-material"}\]. Bisulfite sequencing analyses using the tumor cell lines and pure primary tissues revealed low-density methylation in the unmethylated CpG islands \[[@B36]-[@B39]\]. However, the high tumor cell content examined in this study unambiguously demonstrated LOH events. Therefore, low-level methylation changes are the result of methylation heterogeneity rather than the low tumor cell content.

The hypomethylation of the 5\'-transitional CpG sites was associated with the clinicopathological variables in terms of the similarities to the LOH-H cases (tables [4](#T4){ref-type="table"} and [6](#T6){ref-type="table"}). The LOH-H cases have been reported to be associated with a poor prognosis \[[@B4],[@B6],[@B27]\]. The poor clinical course of gastric cancer might be the result of an interaction between stem-line high-level LOHs and sideline hypomethylation. Considering that the 5\'-transitional CpG sites were methylated to various degrees in a tissue-specific manner \[[@B16]\], the hypomethylation of the transitional CpGs may play a role in the malignant cellular transformation. Extra-embryonic trophoectodermal cells highlight the invasive potential of hypomethylated cells, which penetrate the endometrium during early embryogenesis and implantation. A number of studies have reported hypomethylated trophoblast cells to be well equipped with the biochemical mediators essential for invasive growth and metastasis in a similar manner to transformed tumor cells \[[@B40]\]. Therefore, it appears that the transformation, invasion, and metastasis of tumor cells is dynamically stimulated by the stochastic hypomethylation in response to LOH events rather than by the simple up-regulation of gene expression.

The CpG island of the *RUNX3*gene is frequently hypermethylated in gastric cancer \[[@B41]\]. In this study, the CpG island of the *RUNX3*gene was specifically methylated in the LOH-B gastric cancers (figure [5](#F5){ref-type="fig"}), which were associated with diffuse-type cancers without forming well-defined glandular structures (table [4](#T4){ref-type="table"}). The 5\'-transitional CpGs of genes other than *RUNX3*were more frequently hypomethylated in the LOH-B cases than in the LOH-L and MSI cases (figure [6C](#F6){ref-type="fig"}). The *RUNX3*gene plays a key role in controlling many of the genes associated with the differentiation of gastric epithelial cells \[[@B42]\]. The hypermethylated CpG island of the *RUNX3*gene might be responsible for extensive gene inactivation in gastric epithelial cells developing into diffuse-type cancers. Accordingly, silencing of such master genes should cause widespread alterations in the intronic retroelement transcripts and increase the hypomethylation changes in the transitional area.

The CpG island of the *MLH1*gene was specifically hypermethylated in the MSI cases, in which the hypermethylation of the 5\'-transitional CpGs was most frequent (figure [6D](#F6){ref-type="fig"}). This is in agreement with previous studies reporting that the MSI-positive gastrointestinal cancers accompany the frequent hypermethylation of CpG islands \[[@B38],[@B43]\]. MSI-associated hypermethylation is frequently observed in the intestinal metaplasia and adenoma \[[@B36],[@B39]\], and the MSI cases has been reported to have a favourable clinical outcome even in large-sized tumors \[[@B6],[@B27]\]. In this study, the 5\'-transitional CpGs were infrequently hypermethylated in gastric cancers with a lymphatic and venous invasion and an advanced stage (table [6](#T6){ref-type="table"}). It is likely that hypermethylation of the transitional CpGs can play more of a role in the initiation of a gastric cancer \[[@B44]\], rather than its progression.

Conclusion
==========

A dosage compensation mechanism is believed to maintain a balance in the dose of L1 elements, which initiate the long-distance spread of methylation involving the genome-wide as well as transitional CpGs. The transitional methylated CpG sites not completely protected by the *Alu*elements were hypomethylated in association with LOH events in gastric cancers. This suggests that an irreversible unbalanced decrease in the genomic dose reduces the spread of L1 methylation in the 5\'-end regions of genes in gastric cancers.
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![**Representative autoradiographs of microsatellite analysis (A) and standard curves for methylation and unmethylation MSP amplification (B) using a radioisotope**. (A) A \"multiplex, hot-start\" method was applied to the PCR-based loss of heterozygosity (LOH) analysis. Forty microsatellite allelic loci were amplified in 25 reaction mixtures each of which contained one (10 mixtures) or two (15 mixtures) pairs of primers. A mixture of different-sized two to four amplicons was loaded onto one lane. A total of 80 microsatellite amplicons from each specimen were run simultaneously on one sequencing gel. Case 1 had high-level LOHs involving chromosome 4p, 5q, 9p, 13q, 17p, and 18q. The normal (N) and the corresponding tumor (T) DNAs are indicated above or below each microsatellite amplicon. The asterisk indicates a LOH. (B) The genomic DNA universally methylated by DNA methylase (CpGenome Universal Methylated DNA, Chemicon, Temecula, CA) was used as the methylated control DNA. The PCR DNA, which had been amplified by the universal primer (5\'-CCG ACT CGA GNN NNN NAT GTG G-3\'), was used as the unmethylated control DNA. Variable mixtures of the two opposite control DNAs according to their PCR intensity of 20 ng/μl were amplified using a set of MSP primers for the non-island CpGs of the *TFF2*gene. The proportion of methylated and unmethylated CpGs was calculated using the following formula: Methylation or unmethylation proportion (%) = (methylation or unmethylation intensity/(methylation + unmethylation intensity)) × 100. The relative band intensities of the methylation (M, closed circle) and unmethylation (U, open circle) primer set were plotted as a function of the control DNA content. The amplification intensity ratio of the MSP primer set increased linearly with increasing percentage of the corresponding control DNA in the MSP mixtures.](1471-2407-6-180-1){#F1}

![**Schematic diagram of CpG islands and retroelement distributions in the 5\'-end regions of 20 genes**. A total of 32 CpG amplicon sites from 20 genes were examined using the methylation-specific PCR (MSP) primer sets. The CpG islands of the *CDH1*, *RABGEF1*, *STAG1*, and *MYBPC2*genes were neighbored by the high-density *Alu*elements at distances of ≤ 1 kb. The *VDR*, *ESR2*, *MLH1*, *FLJ43855*, *MYBPC2*, *PTEN*, and *CDKN2A*genes confronted by a low density of *Alu*, L1, and LTR elements at a distance of 2--6 kb were examined at the boundary of CpG islands. The *PAX5*, *RUNX2*, and *RUNX3*genes contained long CpG islands bordered by a few retroelements at distances of \> 6 kb. The genes containing no CpG islands are confronted by the L1 elements (*MAGEA2*and *TFF2*), a low density of *Alu*elements (*SERPINB5*and *DDX53*), or a high density of *Alu*and L1 elements (*MSLN*). The *VDR*, *CDKN2A*, *RUNX2*, *RUNX3*, *KIAA1752*, and *MUC8*genes were examined at the intragenic CpG sites of the CpG islands as well. The MSP primer sites were located in close proximity to the transcription start sites without CpG islands.](1471-2407-6-180-2){#F2}

![**Representative autoradiographs of semiquantitative methylation analysis (A) and the number and position of the methylated CpGs identified by the sequencing of common PCR DNA (B)**. (A) The 5\'-transitional CpG sites generated a wide range of methylated and unmethylated PCR band intensities from the bisulfite-modified DNA from Case 1, with a high-level chromosomal loss, and Case 26, with a low-level chromosomal loss. The lanes marked U and M indicate the PCR bands of the unmethylation and methylation primer sets, respectively. The level of the methylated CpGs calculated from a standard MSP curve is indicated below the lanes. (B) For the same cases, the content of methylated CpGs was estimated from the common PCR DNA containing both the methylated and unmethylated CpGs. Ten common PCR clones per DNA sample were sequenced. The content of methylated CpGs is indicated as a percentage on the left side of each CpG methylation map. The different methylation results between the MSP bands and the common PCR DNAs are indicated by an asterisk.](1471-2407-6-180-3){#F3}

![**Distributions of the *Alu*, L1, and LTR retroelements in the 5\'-end regions of the human genes**. (A) The proportion of *Alu*, L1, and LTR elements in a 1-kb nucleotide bin were plotted separately in both extragenic and intragenic 10-kb segments. (B) The transitional area is demarcated by the distance between the 5\'(3\')-end of a CpG island and the extragenic (intragenic) nearest retroelements. The number of genes (C) and the mean extent of the transitional area (D) were calculated according the position and type of the nearest retroelements.](1471-2407-6-180-4){#F4}

![**Methylation profiles of the CpG islands and the 5\'-transitional CpGs examined in the normal (N) and tumor (T) tissues of gastric cancer patients using semiquantitative methylation-specific PCR analysis**. The methylation status was classified into 5 levels. Gastric cancers were classified into four microsatellite genotypes. The level of methylation and the classification of the microsatellite genotypes are detailed in the \"Materials and Methods\" section. All the information regarding the methylation analysis is listed in table 1 and 2. CpG sites are indicated by the name of the gene and the distance from the transcription start site.](1471-2407-6-180-5){#F5}

![**Relationships between methylation alterations and the number of chromosomal losses in gastric cancers**. The frequency of hypomethylation (A) and hypermethylation (B) detected in 14 transitional CpG amplicons was plotted as a function of the chromosomal losses. The correlation coefficients were calculated using Pearson\'s correlation analysis. The correlation between methylation alterations and chromosomal losses is shown with the line of best fit. The mean frequency of hypomethylation (C) and hypermethylation (D) was compared among four microsatellite genotypes.](1471-2407-6-180-6){#F6}

###### 

Summary of 20 genes examined by methylation analysis

  Gene symbol       Synonym        Gene description                                                 Accession no.
  ----------------- -------------- ---------------------------------------------------------------- ------------------------
  CpG islands                                                                                       
   *CDH1*           *E-CADHERIN*   Cadherin 1, type 1, E-cadherin (epithelial)                      [NM_004360](NM_004360)
   *RABGEF1*        *AJ250042*     RAB guanine nucleotide exchange factor (GEF) 1                   [NM_014504](NM_014504)
   *STAG1*          *SA1*          Stromal antigen 1                                                [NM_005862](NM_005862)
   *MYBPC2*         *AJ250042*     Myosin binding protein C, fast type                              [NM_004533](NM_004533)
   *VDR*            *J03258*       Vitamin D (1,25- dihydroxyvitamin D3) receptor                   [NM_000376](NM_000376)
   *ESR2*           *AF051428*     Estrogen receptor 2 (ER beta)                                    [NM_001437](NM_001437)
   *MLH1*           *HMLH1*        MutL homolog 1, colon cancer, nonpolyposis type 2                [NM_000249](NM_000249)
   *FLJ43855*       *AK125843*     similar to sodium- and chloride-dependent creatine transporter   [NM_198857](NM_198857)
   *PTEN*           *BZS*          Phosphatase and tensin homolog                                   [NM_000314](NM_000314)
   *CDKN2A*         *P16*          Cyclin-dependent kinase inhibitor 2A                             [NM_000077](NM_000077)
   *PAX5*           *AY463952*     Paired box gene 5 (B-cell lineage specific activator)            [NM_016734](NM_016734)
   *RUNX2*          *CBFA1*        Runt-related transcription factor 2                              [NM_004348](NM_004348)
   *RUNX3*          *CBFA3*        Runt-related transcription factor 3                              [NM_004350](NM_004350)
   *KIAA1752*                      Homo sapiens mRNA for KIAA1752 protein                           [AB051539](AB051539)\*
   *MUC8*                          Mucin 8, tracheobronchial                                        [U14383](U14383)\*
  Non-island CpGs                                                                                   
   *MAGEA2*         *MAGE-A2*      Melanoma antigen family A, 2                                     [NM_005361](NM_005361)
   *DDX53*          *CAGE*         DEAD (Asp-Glu-Ala-Asp) box polypeptide 53                        [NM_182699](NM_182699)
   *TFF2*           *SML1*         Trefoil factor 2 (spasmolytic protein 1)                         [NM_005423](NM_005423)
   *SERPINB5*       *MASPIN*       Serpin peptidase inhibitor, clade B (ovalbumin), member 5        [NM_002639](NM_002639)
   *MSLN*           *MPF*          Mesothelin isoform 2 precursor                                   [NM_013404](NM_013404)

\*GenBank accession number.

###### 

CpG dinucleotides examined by methylation-specific polymerase chain reaction

                                            Primer position\*   Intensity ratio†                      
  ------------ --------- ------ ------ ---- ------------------- ------------------ ------ ----------- ------
  *CDH1*       16q22     0      0.73   70   -78                 -76                0.92   0.49/0.51   0.94
  *RABGEF1*    7q11      -0.2   1.00   67   -285                -283               0.9    0.46/0.54   0.91
  *STAG1*      3q22      -0.4   0.95   62   -493                -490               0.93   0.51/0.49   0.91
  *MYBPC2*     19q13     -1.2   0.61   61   -1,226              -1,224             0.92   0.48/0.52   0.94
                         -0.6   0.83   67   -742                -742               0.9    0.51/0.49   0.88
  *VDR*        12q13     -0.7   0.71   58   -728                -727               0.92   0.51/0.49   0.92
                         +0.1   0.84   63   +45                 +45                0.95   0.51/0.49   0.94
  *ESR2*       14q23     -0.9   0.66   59   -983                -986               0.85   0.48/0.52   0.91
  *MLH1*       3p22      -1.0   0.43   49   -1,098              -1,098             0.93   0.51/0.49   0.95
                         -0.6   0.85   63   -660                -655               0.94   0.48/0.52   0.93
  *FLJ43855*   16p11     -1.1   0.62   55   -1147               -1147              0.89   0.48/0.52   0.90
  *PTEN*       10q23     -1.4   0.66   62   -1,425              -1,425             0.93   0.52/0.48   0.91
                         -0.9   0.86   62   -953                -953               0.94   0.51/0.49   0.93
  *CDKN2A*     9p21      -1.5   0.77   65   -1,580              -1,575             0.9    0.47/0.53   0.93
                         0      1.10   65   -85                 -85                0.91   0.47/0.53   0.91
                         +0.8   0.48   51   776                 775                0.93   0.51/0.49   0.96
  *PAX5*       9p13      -1.0   0.50   63   -1,056              -1,054             0.92   0.52/0.48   0.90
  *RUNX2*      6p21      -3.8   0.25   36   -3,883              -3,883             0.9    0.48/0.52   0.93
                         -3.0   0.71   55   -3,061              -3,061             0.91   0.49/0.51   0.92
                         -0.7   0.81   62   -852                -850               0.93   0.52/0.48   0.92
                         +1.6   0.63   53   1573                1573               0.92   0.47/0.53   0.94
  *RUNX3*      1p36      -1.7   0.82   60   -1,790              -1,790             0.89   0.46/0.54   0.9
                         -0.5   0.94   75   -559                -559               0.91   0.48/0.52   0.9
                         -0.1   1.07   76   -219                -217               0.92   0.5/0.5     0.93
                         +1.0   0.79   59   952                 952                0.91   0.49/0.51   0.93
  *KIAA1752*   16q12     +0.4   0.42   41   391                 391                0.92   0.48/0.52   0.94
  *MUC8*       12q24     +2.0   0.42   59   1,909               1,909              0.94   0.49/0.51   0.95
  *MAGEA2*     Xq28      0      0.56   64   -81                 -75                0.9    0.54/0.46   0.91
  *DDX53*      Xq22.11   0      0.53   59   -71                 -102               0.94   0.48/0.52   0.94
  *TFF2*       21q22     -0.2   0.32   57   -251                -251               0.96   0.5/0.5     0.96
  *SERPINB5*   18q21     -0.3   0.62   51   -315                -308               0.93   0.51/0.49   0.94
  *MSLN*       16q13     -0.8   0.52   57   -827                -827               0.92   0.47/0.53   0.93

\*The genomic position was calculated from the May 2004 human reference sequence.

†The relative proportion of unmethylation (U) and methylation (M) band intensity against the total band intensity.

‡U/M indicates a PCR mixture containing the same amount of the universal methylated and unmethylated DNA.

###### 

The density of methylation estimated by semiquantitative methylation-specific PCR analysis and sequencing of common PCR DNA

                                      Methylation-specific PCR              
  --------------------- ---- -------- -------------------------- ---------- ---------------
  *MYBPC2*, -1.2 kb     1    Normal   Level 4                    Level 4    53/70‡ (76%)
                             Tumor    Level 4                    Level 4    48/70 (69%)
                        26   Normal   Level 4                    Level 4    47/70 (67%)
                             Tumor    Level 3                    No band    32/70 (46%)
  *VDR*, -0.7 kb        1    Normal   Level 1                    Level 1    4/130 (3%)
                             Tumor    Level 1                    Level 1    12/130 (9%)
                        26   Normal   Level 2                    Level 2    44/130 (34%)
                             Tumor    Level 3                    Level 3    64/130 (49%)
  *MLH1*, -1.0 kb       1    Normal   Level 3                    Level 3    14/30 (47%)
                             Tumor    Level 2                    Level 3†   10/30 (33%)
                        26   Normal   Level 2                    No band    9/30 (30%)
                             Tumor    Level 4†                   Level 3    17/30 (57%)
  *MLH1*, -0.6 kb       1    Normal   Level 1                    Level 1    0/200 (0%)
                             Tumor    Level 1                    Level 1    0/200 (0%)
                        26   Normal   Level 1                    Level 1    4/200 (2%)
                             Tumor    Level 1                    Level 1    4/200 (2%)
  *CDKN2A*, -1.5 kb     1    Normal   Level 2                    Level 2    19/60 (32%)
                             Tumor    Level 1                    Level 1    5/60 (8%)
                        26   Normal   Level 2                    Level 2    13/60 (22%)
                             Tumor    Level 5                    No band    54/60 (90%)
  *CDKN2A*, 0 kb        1    Normal   Level 1                    Level 1    0/110 (0%)
                             Tumor    Level 1                    Level 1    0/110 (0%)
                        26   Normal   Level 1                    Level 1    0/110 (0%)
                             Tumor    Level 4                    Level 3†   76/110 (69%)
  *RUNX2*, -3.0 kb      1    Normal   Level 1                    Level 1    8/60 (13%)
                             Tumor    Level 1                    Level 1    8/60 (13%)
                        26   Normal   Level 2†                   No band    11/60 (18%)
                             Tumor    Level 2†                   Level 1    9/60 (15%)
  *RUNX3*, -1.7 kb      1    Normal   Level 1                    Level 1    6/70 (10%)
                             Tumor    Level 3                    Level 3    38/70 (54%)
                        26   Normal   Level 2                    Level 3†   27/70 (39%)
                             Tumor    Level 4                    Level 3†   45/70 (64%)
  *MAGEA2*, 0 kb        1    Normal   Level 5                    Level 5    106/110 (96%)
                             Tumor    Level 2                    Level 2    41/110 (37%)
                        26   Normal   Level 5                    Level 5    104/110 (95%)
                             Tumor    Level 5                    Level 5    103/110 (94%)
  *TFF2*, -0.2 kb       1    Normal   Level 2                    Level 3†   21/60 (35%)
                             Tumor    Level 2                    Level 3†   19/60 (32%)
                        26   Normal   Level 3                    Level 3    32/60 (53%)
                             Tumor    Level 2†                   Level 3    25/60 (42%)
  *SERPINB5*, -0.3 kb   1    Normal   Level 3                    Level 3    36/70 (51%)
                             Tumor    Level 2†                   No band    31/70 (44%)
                        26   Normal   Level 2                    Level 3†   26/70 (37%)
                             Tumor    Level 2                    No band    27/70 (39%)
  *MSLN*, -0.8 kb       1    Normal   Level 5                    Level 5    66/70 (94%)
                             Tumor    Level 3                    Level 4†   38/70 (54%)
                        26   Normal   Level 4                    Level 4    51/70 (73%)
                             Tumor    Level 5                    Level 5    61/70 (87%)

\*CpG sites are indicated by the name of the gene and the distance from the transcription start site.

†Different results between methylation-specific PCR and common PCR DNA.

‡\'/\' separates the number of the methylated CpGs and the total CpGs.

###### 

Clinicopathological characteristics of gastric cancers according to the level of loss of heterozygosity (LOH) and microsatellite instability\*

                          Total         High LOH      Low LOH       p†      Baseline LOH   Microsatellite instability
  ----------------------- ------------- ------------- ------------- ------- -------------- ----------------------------
  No. of patients         50            20            19                    6              5
  Age (years)                                                                              
   Mean ± SD              59.6 ± 12.6   60.5 ± 11.7   61.1 ± 11.6   0.883   55.0 ± 7.9     66.8 ± 7.3
  Tumor size (cm)                                                                          
   Mean ± SD              4.9 ± 2.8     5.2 ± 2.7     4.4 ± 3.1     0.402   4.3 ± 1.8      6.3 ± 3.2
  Sex                                                                                      
   Male                   32            15            12            0.325   3              2
   Female                 18            5             7                     3              3
  Lauren classification                                                                    
   Intestinal             29            10            16            0.032   0              3
   Diffuse                11            5             3                     3              0
   Mixed                  10            5             0                     3              2
  Differentiation                                                                          
   Well                   4             0             3             0.046   0              1
   Moderate               26            11            13                    0              2
   Poor                   20            9             3                     6              2
  Growth pattern                                                                           
   Infiltrative           27            14            9             0.126   2              2
   Expanding              3             0             3                     0              0
   Mixed                  20            6             7                     4              3
  Venous invasion                                                                          
   Yes                    6             4             0             0.059   2              0
   No                     44            16            19                    4              5
  Lymphatic invasion                                                                       
   Yes                    29            16            5             0.001   5              3
   No                     21            4             14                    1              2
  Tumor stage                                                                              
   Early stage            29            8             15            0.015   2              4
   Advanced stage         21            12            4                     4              1

\*The classification of microsatellite genotypes is detailed in the \"Material and Method\" section.

†p values were calculated between the low LOH and high LOH cases by an independent *t*test for the age and tumor size variables and by a Fisher\'s exact test or a *χ*^*2*^test for other variables.

###### 

Methylation alterations in the CpG islands and the 5\'-transitional CpG sites examined in gastric cancers containing high-level and low-level chromosomal losses

                         High-level chromosomal loss (n = 20)   Low-level chromosomal loss (n = 19)                                                               
  ---------------------- -------------------------------------- ------------------------------------- ---------- --------- --------- ----- ----- ------- -------- ---------
  CpG islands                                                                                                                                                     
   *CDH1*, 0 kb          1.2                                    1.0                                   0.083      3 (15)    0 (0)     1.1   1.1   0.560   0 (0)    1 (5)
   *RABGEF1*, -0.2 kb    1.1                                    1.0                                   0.163      2 (10)    0 (0)     1.0   1.0   1       0 (0)    0 (0)
   *STAG1*, -0.4 kb      1.1                                    1.0                                   0.330      1 (5)     0 (0)     1.0   1.0   1       0 (0)    0 (0)
   *MYBPC2*, -0.6 kb     1.6                                    1.6                                   0.757      2 (10)    1 (5)     2.0   2.3   0.090   0 (0)    4 (21)
   *MLH1*, -0.6 kb       1.4                                    1.4                                   1          5 (25)    2 (10)    1.3   1.7   0.153   0 (0)    4 (21)
   *PTEN*, -0.9 kb       1.3                                    1.2                                   0.442      2 (10)    0 (0)     1.1   1.1   0.560   1 (5)    2 (11)
   *CDKN2A*, 0kb         1.1                                    1.0                                   0.330      1 (5)     0 (0)     1.0   1.4   0.072   0 (0)    4 (21)
   *PAX5*, -1.0 kb       2.0                                    1.7                                   0.115      7 (35)    0 (0)     1.9   2.1   0.505   4 (21)   5 (26)
   *RUNX2*, -3.8 kb      4.2                                    3.8                                   0.054      7 (35)    0 (0)     4.2   4.3   0.376   1 (5)    4 (21)
    -3.0 kb              1.8                                    1.8                                   1          5 (25)    5 (25)    2.0   2.0   1       3 (16)   4 (21)
    -0.7 kb              2.1                                    2.0                                   0.575      5 (25)    4 (20)    1.7   1.9   0.266   4 (21)   6 (32)
    +1.6 kb              2.0                                    2.2                                   0.295      3 (15)    5 (25)    2.1   2.5   0.066   2 (11)   7 (37)
   *RUNX3*, -1.7 kb      2.0                                    3.3                                   \<0.0001   0 (0)     14 (70)   2.5   3.3   0.012   0 (0)    12 (63)
    -0.5 kb              1.3                                    1.1                                   0.121      6 (30)    2 (10)    1.8   2.4   0.035   2 (11)   9 (47)
    -0.1 kb              1.2                                    1.0                                   0.042      4 (20)    0 (0)     1.0   1.2   0.042   0 (0)    4 (21)
    +1.0 kb              4.0                                    3.8                                   0.519      6 (30)    5 (25)    3.4   3.8   0.012   0 (0)    7 (37)
   *VDR*, +0.1 kb        1.0                                    1.0                                   1          0 (0)     0 (0)     1.0   1.0   1       0 (0)    0 (0)
   *KIAA1752*, +0.4 kb   2.8                                    2.6                                   0.096      8 (40)    0 (0)     2.1   2.5   0.084   0 (0)    7 (37)
  Transitional CpGs                                                                                                                                               
   *MYBPC2*, -1.2 kb     4.3                                    4.1                                   0.083      4 (20)    0 (0)     4.3   4.2   0.546   5 (26)   2 (11)
   *VDR*, -0.7 kb        1.8                                    1.3                                   0.003      10 (50)   0 (0)     1.5   2.1   0.056   3 (16)   8 (42)
   *ESR2*, -0.9 kb       1.7                                    1.4                                   0.114      6 (30)    0 (0)     1.3   1.5   0.141   0 (0)    4 (22)
   *MLH1*, -1.0 kb       3.1                                    2.5                                   0.050      9 (45)    2 (10)    2.8   3.5   0.035   1 (5)    11 (58)
   *FLJ43855*, -1.1 kb   4.0                                    3.5                                   0.043      10 (50)   2 (10)    3.7   4.1   0.072   2 (11)   8 (42)
   *PTEN*, -1.4 kb       1.4                                    1.1                                   0.062      5 (25)    0 (0)     1.1   1.3   0.119   1 (5)    5 (26)
   *CDKN2A*, -1.5 kb     2.0                                    1.6                                   0.012      10 (50)   2 (10)    2.0   2.8   0.025   3 (16)   10 (53)
    +0.8 kb              4.4                                    3.6                                   0.002      12 (60)   0 (0)     4.1   4.4   0.173   3 (16)   7 (37)
   *MUC8*, +2.0 kb       4.4                                    3.7                                   0.001      9 (45)    0 (0)     4.4   4.2   0.149   6 (32)   2 (11)
   *MAGEA2*, 0 kb        4.8                                    3.4                                   \<0.0001   11 (55)   0 (0)     4.8   4.6   0.336   2 (11)   0 (0)
   *DDX53*, 0 kb         4.2                                    3.7                                   0.051      9 (45)    2 (10)    4.5   3.9   0.096   6 (32)   2 (11)
   *TFF2*, -0.2 kb       2.4                                    2.1                                   0.174      7 (35)    2 (10)    2.2   2.0   0.324   6 (32)   2 (11)
   *SERPINB5*, -0.3 kb   2.7                                    2.2                                   0.080      10 (50)   3 (15)    2.4   2.5   0.598   2 (11)   4 (21)
   *MSLN*, -0.8 kb       4.3                                    3.6                                   0.005      11 (55)   2 (10)    3.5   3.7   0.591   1 (5)    5 (26)

\*CpG sites are indicated by the name of the gene and the distance from the transcription start site.

†p values were calculated by an independent *t*test for the mean values.

###### 

Relationships between methylation alterations and clinicopathological variables in gastric cancers (n = 39) containing high-level and low-level chromosomal losses

                               Mean frequency of methylation alterations\* (%, mean ± SD)                         
  ----------------------- ---- ------------------------------------------------------------ ------- ------------- -------
  Age (years)                                                                                                     
   ≤55                    7    34.7 ± 28.4                                                  0.547   11.2 ± 9.1    0.384
   \>55                   32   29.0 ± 20.1                                                          16.5 ± 15.2   
  Tumor size (cm)                                                                                                 
   ≤5                     24   24.7 ± 16.7                                                  0.056   17.3 ± 15.6   0.359
   \> 5                   15   38.6 ± 27.4                                                          12.9 ± 12.1   
  Sex                                                                                                             
   Male                   27   28.8 ± 22.2                                                  0.619   14.5 ± 15.0   0.514
   Female                 12   32.7 ± 22.9                                                          17.8 ± 13.1   
  Lauren classification                                                                                           
   Intestinal             26   28.0 ± 21.3                                                  0.727   18.1 ± 15.0   0.189
   Diffuse                8    34.8 ± 29.4                                                          13.4 ± 12.9   
   Mixed                  5    32.9 ± 15.6                                                          5.7 ± 9.3     
  Differentiation                                                                                                 
   Well                   3    23.8 ± 10.9                                                  0.671   23.8 ± 8.2    0.169
   Moderate               24   28.6 ± 22.2                                                          17.6 ± 15.3   
   Poor                   12   34.5 ± 24.7                                                          9.5 ± 11.9    
  Growth pattern                                                                                                  
   Infiltrative           23   32.6 ± 25.6                                                  0.639   13.4 ± 12.9   0.221
   Expanding              3    21.4 ± 14.3                                                          28.6 ± 14.3   
   Mixed                  13   27.4 ± 16.7                                                          16.5 ± 16.1   
  Venous invasion                                                                                                 
   Yes                    4    37.5 ± 16.9                                                  0.485   1.8 ± 3.6     0.041
   No                     35   29.2 ± 22.7                                                          17.1 ± 14.3   
  Lymphatic invasion                                                                                              
   Yes                    21   38.8 ± 25.2                                                  0.006   9.5 ± 10.4    0.003
   No                     18   19.8 ± 12.1                                                          22.6 ± 15.3   
  Tumor stage                                                                                                     
   Early stage            23   23.0 ± 15.1                                                  0.015   19.9 ± 15.7   0.023
   Advanced stage         16   40.2 ± 26.9                                                          9.4 ± 9.7     

\*Methylation alterations were detected in 14 transitional CpG amplicons.

†p values were calculated by an independent *t*test.
